Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick P Zarrinkar

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Nature|April 17, 2012
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaCatherine C Smith, Qi Wang, Chen-Shan Chin, et al.
Bioorganic & Medicinal Chemistry Letters|August 4, 2009
Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitorsHitesh K Patel, Robert M Grotzfeld, Andiliy G Lai, et al.
Blood|August 6, 2009
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Patrick P Zarrinkar, Ruwanthi N Gunawardane, Merryl D Cramer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K InhibitionSandra Misale, Jackson P Fatherree, Eliane Cortez, et al.
Nature Biotechnology|January 10, 2008
A quantitative analysis of kinase inhibitor selectivityMazen W Karaman, Sanna Herrgard, Daniel K Treiber, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 28, 2005
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesTodd A Carter, Lisa M Wodicka, Neil P Shah, et al.
Nature Biotechnology|February 16, 2005
A small molecule-kinase interaction map for clinical kinase inhibitorsMiles A Fabian, William H Biggs, Daniel K Treiber, et al.
Cell|January 27, 2018
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific InhibitorMatthew R Janes, Jingchuan Zhang, Lian-Sheng Li, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Nature|April 17, 2012
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaCatherine C Smith, Qi Wang, Chen-Shan Chin, et al.
Bioorganic & Medicinal Chemistry Letters|August 4, 2009
Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitorsHitesh K Patel, Robert M Grotzfeld, Andiliy G Lai, et al.
Blood|August 6, 2009
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Patrick P Zarrinkar, Ruwanthi N Gunawardane, Merryl D Cramer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K InhibitionSandra Misale, Jackson P Fatherree, Eliane Cortez, et al.
Nature Biotechnology|January 10, 2008
A quantitative analysis of kinase inhibitor selectivityMazen W Karaman, Sanna Herrgard, Daniel K Treiber, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 28, 2005
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesTodd A Carter, Lisa M Wodicka, Neil P Shah, et al.
Nature Biotechnology|February 16, 2005
A small molecule-kinase interaction map for clinical kinase inhibitorsMiles A Fabian, William H Biggs, Daniel K Treiber, et al.
Cell|January 27, 2018
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific InhibitorMatthew R Janes, Jingchuan Zhang, Lian-Sheng Li, et al.
Pageof 2